# Andrea M. Gross

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrea-m-gross/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,099 |
| Field | Neurofibromatosis and Schwannoma Cases |
| h-index | 27 |
| i10-index | 52 |
| Last Known Institution | Cincinnati Children's Hospital Medical Center |
| OpenAlex ID | https://openalex.org/A5013034227 |
| ORCID iD | 0000-0003-1646-4531 |
| Works | 214 |

## Researcher papers

- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [SIMKK, a Mitogen-Activated Protein Kinase (MAPK) Kinase, Is a Specific Activator of the Salt Stress–Induced MAPK, SIMK](https://scholariq.org/papers/simkk-a-mitogen-activated-protein-kinase-mapk-kinase-is-a-specific-activator-of/)
- [Synthetic Peptides as Protein Mimics](https://scholariq.org/papers/synthetic-peptides-as-protein-mimics/)
- [Management of neurofibromatosis type 1-associated plexiform neurofibromas](https://scholariq.org/papers/management-of-neurofibromatosis-type-1-associated-plexiform-neurofibromas/)
- [Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1](https://scholariq.org/papers/association-of-plexiform-neurofibroma-volume-changes-and-development-of-clinical/)
- [MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus](https://scholariq.org/papers/mek-inhibitors-for-neurofibromatosis-type-1-manifestations-clinical-evidence-and/)
- [Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas](https://scholariq.org/papers/long-term-safety-and-efficacy-of-selumetinib-in-children-with-neurofibromatosis/)
- [A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors](https://scholariq.org/papers/a-monosaccharide-residue-is-sufficient-to-maintain-mouse-and-human-igg-subclass/)
- [Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions](https://scholariq.org/papers/longitudinal-evaluation-of-peripheral-nerve-sheath-tumors-in-neurofibromatosis/)
- [The Lipid A substructure of the <i>Sinorhizobium meliloti</i> lipopolysaccharides is sufficient to suppress the oxidative burst in host plants](https://scholariq.org/papers/the-lipid-a-substructure-of-the-i-sinorhizobium-meliloti-i-lipopolysaccharides/)
- [A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib](https://scholariq.org/papers/a-mixed-methods-study-of-medication-adherence-in-adults-with-neurofibromatosis/)

## Researcher topics

- [Neurofibromatosis and Schwannoma Cases](https://scholariq.org/topics/neurofibromatosis-and-schwannoma-cases/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)

## Researcher university

- [Cincinnati Children's Hospital Medical Center](https://scholariq.org/institutions/cincinnati-children-s-hospital-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.